Business
Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns
Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAmarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns\n\n\n\n\n\nAmarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns\nESS reduces mortality and repeated donor skin harvesting in children\nPR Newswire\nSAN FRANCISCO, August 8, 2016\n\n\n\nSAN FRANCISCO, August 8, 2016 /PRNewswire/ --\n\nAmarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced the publication of a 16-subject clinical study of Engineered Skin Substitute (\"ESS,\" or \"Permaderm™\") in children with life-threatening severe burns. In this study, ESS was compared with the standard of care (split-thickness autograft \"AG\") for treating full-thickness (dermal and epidermal layers of skin) life-threatening pediatric severe burns covering a total body surface area (TBSA) of 50% or greater. Amarantus' wholly-owned subsidiary Cutanogen Corporation is pursuing the development of ESS towards regulatory approval for the treatment of life-threatening severe burns. ESS has received orphan drug designation from the U.S. FDA in the treatment of full-thickness burns covering over 50% TBSA.\n\nThe article entitled \"Randomized, Paired-Site Comparison of Autologous Engineered Skin Substitutes and Split-Thickness Skin Graft for Closure of Extensive, Full-Thickness Burns\" was published online in the July edition of the Journal of Burn Care and Research (Boyce, et al, 2016). A copy of the article can be purchased online at: http://journals.lww.com/burncareresearch/Abstract/publishahead/Randomized,_Paired_Site_Comparison_of_Autologous.98555.aspx.\n\n\"The publication of the human clinical data from the compassionate use study of ESS in the treatment of pediatric severe burns provides important detail surrounding the unprecedented results generated in the study, where all patients who survived long enough to receive ESS treatment ultimately survived, whereas the standard of care for the comparable patient population has a mortality rate in excess of 30%,\" said Dr. David Ahrenholz, retired President of the American Burn Association. \"ESS has the potential to establish ...